Pankreaskarzinom – Screening oder Surveillance: Was ergibt Sinn?

Sirtl, Simon; Vornhuelz, Marlies; Hofmann, Felix O.; Mayerle, Julia und Beyer, Georg (2022): Pankreaskarzinom – Screening oder Surveillance: Was ergibt Sinn? In: Gastroenterologie, Bd. 17, Nr. 6: S. 375-386

Abstract

Background Despite continuous improvement of diagnostic and therapeutic procedures, the number of new pancreatic ductal adenocarcinoma (PDAC) cases diagnosed annually almost equals the number of PDAC-related deaths. Prerequisite for curative treatment is a resectable tumor at the time of diagnosis. Individuals with genetic and/or familial risk profiles should therefore be screened and included in structured surveillance programs. Objectives Description of the status quo and usefulness of current PDAC screening and surveillance concepts. Methods A selective literature search of current national and international guidelines including underlying literature was performed. Results Nearly half of pancreatic cancer cases are missed by currently available surveillance programs, even in high-risk cohorts. Magnetic resonance imaging and endoscopic ultrasound supplemented by CA19-9 (+/- HbA(1c)) are not accurate enough to ensure robust earlier pancreatic cancer detection. Complementary biomarker panels will take on a crucial diagnostic role in the future.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 2731-7420
• Sprache: Deutsch